Form 4: OrbiMed Sells 500,000 PMV Pharma Shares in Pre-Planned Trade

OrbiMed Advisors, a 10% owner and director of PMV Pharmaceuticals, reported a pre-planned sale of 500,000 common shares at $1.80 per share.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, entities associated with a director and 10% owner of PMV Pharmaceuticals, Inc. (PMVP), reported the sale of 500,000 shares of common stock.
• The transaction occurred on September 10, 2025, at a price of $1.80 per share.
• This sale was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the transaction, OrbiMed entities indirectly beneficially own 5,975,291 shares of PMV Pharmaceuticals common stock.
• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of a significant block of shares by a 10% owner and director, even under a Rule 10b5-1 plan, generally indicates a reduction in exposure and can be perceived negatively by the market. While the pre-planned nature mitigates the immediate implication of new negative information, the volume and identity of the seller are notable.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on new, non-public information.

Negatives

• A significant sale of 500,000 shares by a 10% owner and director could be perceived negatively by the market, potentially signaling a reduction in exposure or a need for liquidity.
• The sale price of $1.80 per share might be lower than previous trading prices, depending on market conditions around the transaction date.

Risks

• Market perception risk: Large insider sales, even if pre-planned, can sometimes lead to negative market sentiment or downward pressure on the stock price.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any.
• This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

This transaction is an isolated insider trading event and does not directly reflect broader industry trends. However, institutional investor activity in the biotechnology and pharmaceutical sectors is closely watched for sentiment indicators.

Related Party Transactions

• The sale of 500,000 shares of common stock by OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, entities associated with a director and 10% owner of PMV Pharmaceuticals, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May interpret the sale by a significant institutional investor as a negative signal, potentially leading to downward pressure on the stock price.
• Company Management: The transaction itself does not directly impact company operations but could influence investor relations and market sentiment.

Key Dates

Recommendation

A significant sale by a 10% owner and director, even if pre-planned under a Rule 10b5-1 plan, suggests a reduction in conviction or a portfolio rebalancing. While not an immediate 'sell' signal due to the pre-planned nature, it warrants caution. Investors should hold and monitor the company's performance and future insider activity for further directional cues.

Keywords

PMV Pharmaceuticals, PMVP, OrbiMed Advisors, Insider Sale, Form 4, 10b5-1 Plan, Biotechnology, Pharmaceuticals, Equity Transaction, Institutional Investor